GILEAD SCIENCES, INC. Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31)
GILEAD SCIENCES, INC. (GILD) reported Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31) of -$451.00 thousand for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-05-08.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeNetOfTax · last filed 2013-05-08
- GILEAD SCIENCES, INC. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for the quarter ending 2013-03-31 was -$451.00K.
- GILEAD SCIENCES, INC. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for the quarter ending 2012-12-31 was -$24.30M, a 211.33% decline year-over-year.
- GILEAD SCIENCES, INC. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for the quarter ending 2012-09-30 was -$37.45M, a 188.97% decline year-over-year.
- GILEAD SCIENCES, INC. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for the quarter ending 2012-06-30 was -$14.51M, a 173.14% decline year-over-year.
- GILEAD SCIENCES, INC. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for fiscal 2012 was -$86.64M, a 216.67% decline from fiscal 2011.
- GILEAD SCIENCES, INC. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for fiscal 2011 was $74.26M.
- GILEAD SCIENCES, INC. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for fiscal 2010 was -$67.86M.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31) 3 month | Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31) 6 month | Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31) 9 month | Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31) 12 month |
|---|---|---|---|---|
| 2013-03-31 | -$451.00K 10-Q · filed 2013-05-08 | -$24.75M derived: sum of 2 quarters · filed 2013-05-08 | -$62.20M derived: sum of 3 quarters · filed 2013-05-08 | -$76.71M derived: sum of 4 quarters · filed 2013-05-08 |
| 2012-12-31 | -$24.30M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | -$61.75M derived: sum of 2 quarters · filed 2013-02-27 | -$76.26M derived: sum of 3 quarters · filed 2013-02-27 | -$86.64M 10-K · filed 2013-02-27 |
| 2012-09-30 | -$37.45M 10-Q · filed 2012-11-06 | -$51.96M derived: sum of 2 quarters · filed 2012-11-06 | -$62.34M 10-Q · filed 2012-11-06 | -$40.96M derived: sum of 4 quarters · filed 2013-05-08 |
| 2012-06-30 | -$14.51M 10-Q · filed 2012-08-01 | -$25.29M 10-Q · filed 2012-08-01 | -$3.51M derived: sum of 3 quarters · filed 2013-05-08 | $38.58M derived: sum of 4 quarters · filed 2013-05-08 |
| 2012-03-31 | -$10.83M 10-Q · filed 2013-05-08 | $11.00M derived: sum of 2 quarters · filed 2013-05-08 | $53.09M derived: sum of 3 quarters · filed 2013-05-08 | $72.93M derived: sum of 4 quarters · filed 2013-05-08 |
| 2011-12-31 | $21.82M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $63.92M derived: sum of 2 quarters · filed 2013-02-27 | $83.76M derived: sum of 3 quarters · filed 2013-02-27 | $74.26M 10-K · filed 2013-02-27 |
| 2011-09-30 | $42.09M 10-Q · filed 2012-11-06 | $61.93M derived: sum of 2 quarters · filed 2012-11-06 | $52.43M 10-Q · filed 2012-11-06 | |
| 2011-06-30 | $19.84M 10-Q · filed 2012-08-01 | $11.01M 10-Q · filed 2012-08-01 | ||
| 2010-12-31 | -$67.86M 10-K · filed 2013-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |